Rapport Therapeutics
Watchlist
Rapport Therapeutics: Study Data, Stock Placement, and Insider Purchases!
Reading Time: 2 minutes
Rapport Therapeutics Inc. (RAPP) focuses on developing precision medicines for neurological and psychiatric disorders. The company operates under the premise that receptor-associated proteins (RAPs) play a crucial role in regulating receptor expression and function. Their main compound, RAP-219, is being studied not only for focal epilepsy but also for other conditions such as bipolar mania and diabetic peripheral neuropathic pain. By targeting the modulation of AMPA receptors, the drug aims to offer greater efficacy with fewer side effects. ...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
